Pfizer-Allergan $160 billion merger sparks debate

Global Business

U.S. pharmaceutical giant Pfizer is buying Botox maker Allergan for 160 billion dollars.

But size isn’t everything. The deal involves Pfizer shifting its headquarters to Ireland and that means it can slash its tax bill.
It has stoked a very contentious debate here in the U.S. and looks set to be a big issue in the presidential election.

CCTV America’s Shraysi Tandon reports.

Pfizer-Allergan $160 billion merger sparks debate

Pfizer-Allergan $160 billion merger sparks debate

U.S. pharmaceutical giant Pfizer is buying Botox maker Allergan for 160 billion dollars. But size isn't everything. The deal involves Pfizer shifting its headquarters to Ireland and that means it can slash its tax bill. It has stoked a very contentious debate here in the U.S. and looks set to be a big issue in the presidential election. CCTV America's Shraysi Tandon reports.
Download Video


David Nelson on tax inversion

CCTV America’s Michelle Makori spoke to David Nelson. He is the chief strategist at Belpointe.

David Nelson on tax inversion

David Nelson on tax inversion

CCTV America's Michelle Makori spoke to David Nelson. He is the chief strategist at Belpointe.
Download Video